Global patent landscape of synthetic drugs for melasma (2015–2025): innovation trends, mechanistic shifts, and translational challenges
- 14 September 2026
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 36 (11) , 1029-1044
Abstract
1. Melasma is one of the most prevalent forms of facial hyperpigmentation worldwide, characterized by its chronic, acquired, and recurrent nature, and mainly affecting women of reproductive age. Th...Keywords
This publication has 57 references indexed in Scilit:
- Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applicationsMolecular Therapy Nucleic Acids, 2024
- An Update on New and Existing Treatments for the Management of MelasmaAmerican Journal of Clinical Dermatology, 2024
- Self-Esteem, Depression, Anxiety and Quality of Life in Patients with Melasma Living in a Sunny Mediterranean Area: Results from a Prospective Cross-Sectional StudyDermatology and Therapy, 2023
- Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse modelMolecular Therapy - Methods & Clinical Development, 2023
- Update on Melasma—Part II: TreatmentDermatology and Therapy, 2022
- Tissue Stem Cells: Architects of Their NichesCell Stem Cell, 2020
- Melanocyte activation and skin barrier disruption induced in melasma patients after 1064 nm Nd:YAG laser treatmentLasers in Medical Science, 2018
- Melasma: an Up-to-Date Comprehensive ReviewDermatology and Therapy, 2017
- Mechanism of inhibition of melanogenesis by hydroquinoneBiochimica et Biophysica Acta (BBA) - General Subjects, 1991
- Topical Use of Hydroquinone for DepigmentationJAMA, 1965